Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase 1 2Phase 3 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 38Sarcoma 29Lymphoid 10Thoracic 6Other hematologic neoplasm 6Genitourinary 6Gastrointestinal 5Endocrine 5Dermatologic 5Breast 5Other solid neoplasm 4Head & Neck 3Gynecologic 3Plasma cell 2NET 2Myeloid 1

Conditions

Neuroendocrine Tumors 60Neoplasms 7Gastro-enteropancreatic neuroendocrine tumor 7Carcinoid Tumor 6Breast Neoplasms 6Pheochromocytoma 5Colorectal Neoplasms 5Carcinoma, Renal Cell 5Adenoma, Islet Cell 5Urinary Bladder Neoplasms 4Thyroid Neoplasms 4Paraganglioma 4Neoplasm Metastasis 4Lung Neoplasms 4Carcinoma, Neuroendocrine 4Carcinoma, Hepatocellular 4Brain Neoplasms 4Small Cell Lung Carcinoma 3Prostatic Neoplasms 3Pancreatic Neoplasms 3Melanoma 3Carcinoma, Medullary 3Adrenocortical Carcinoma 3Uveal Melanoma 2Uterine Cervical Neoplasms 2Testicular Neoplasms 2Sarcoma 2Neuroectodermal Tumors, Primitive 2Lymphoma 2Liver Neoplasms 2

Interventions

trifluridine tipiracil drug combination 1pegfilgrastim 1Temozolomide 1Filgrastim 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Neuroectodermal Tumors, Primitive × NET × Clear all
NCT02943733 2022-09-23

Safety of TAS-102 in Combination With Temozolomide for Metastatic Pancreatic NETs

University of Wisconsin, Madison

Phase 1 Terminated
18 enrolled
EndocrineNET

Neoplasms, Neuroectodermal Tumors, Primitive, Neuroendocrine Tumors

NCT02355535 2020-09-24

Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies - Component 1

Vanquish Oncology, Inc.

Phase 1 Completed
48 enrolled
EndocrineNET

Adenoma, Islet Cell, Neuroectodermal Tumors, Primitive, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡